BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33765714)

  • 41. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
    Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
    Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
    Liu YP; Ling Y; Zhang YP; Liu BR
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
    Geng N; Ding CM; Liu ZK; Song S; Hu WX
    Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Association of
    Yang F; Xiong P; Yuan XL; Liu CR; Ran LJ; Yang Y; Li JY
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2017 Mar; 35(3):189-192. PubMed ID: 28511303
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
    Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
    Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
    Park JH; Kim NS; Park JY; Chae YS; Kim JG; Sohn SK; Moon JH; Kang BW; Ryoo HM; Bae SH; Choi GS; Jun SH
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1135-42. PubMed ID: 20091185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment.
    Bai M; Li ZG; Ba Y
    Int J Gen Med; 2021; 14():1041-1055. PubMed ID: 33790633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A association of genetic polymorphisms of XRCC1 and damage levels in workers exposed to coal tar pitch].
    Zhang F; Sun XC; Lu CD; Zhang W; Shao H; Wang ZX
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2017 Jan; 35(1):7-10. PubMed ID: 28241694
    [No Abstract]   [Full Text] [Related]  

  • 49. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
    Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
    Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
    Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
    World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China.
    Kong J; Liu Z; Cai F; Xu X; LiuI J
    Clinics (Sao Paulo); 2018 Dec; 73():e455. PubMed ID: 30517302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
    Liu JY; Zhu BR; Wang YD; Sun X
    Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
    Li S; Zhu L; Yao L; Xia L; Pan L
    BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
    Suh KW; Kim JH; Kim DY; Kim YB; Lee C; Choi S
    Ann Surg Oncol; 2006 Nov; 13(11):1379-85. PubMed ID: 17009149
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Association between XRCC1 polymorphisms and chromosome damage in workers exposed to benzene in jewelcrafting industry].
    Huang LJ; Peng ZM; Zhang XZ; Yin JB; Chi HC
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2016 Jun; 34(6):416-20. PubMed ID: 27514548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 58. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
    Xu C; Wang X; Zhang Y; Li L
    Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The association of c.1471G>A genetic polymorphism in XRCC1 gene with lung cancer susceptibility in Chinese Han population.
    Wang L; Chen Z; Wang Y; Chang D; Su L; Guo Y; Liu C
    Tumour Biol; 2014 Jun; 35(6):5389-93. PubMed ID: 24519065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.
    Yin Z; Zhou B; He Q; Li M; Guan P; Li X; Cui Z; Xue X; Su M; Ma R; Bai W; Xia S; Jiang Y; Xu S; Lv Y; Li X
    BMC Cancer; 2009 Dec; 9():439. PubMed ID: 20003463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.